Works matching AU Xiaorui Fu

Results: 77
    1
    2
    3
    4
    5
    6
    7

    Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure.

    Published in:
    Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.687374
    By:
    • Hu, Junxia;
    • Wang, Xin;
    • Chen, Fei;
    • Ding, Mengjie;
    • Dong, Meng;
    • Yang, Wanqiu;
    • Yin, Meifeng;
    • Wu, Jingjing;
    • Zhang, Lei;
    • Fu, Xiaorui;
    • Sun, Zhenchang;
    • Li, Ling;
    • Wang, Xinhua;
    • Li, Xin;
    • Guo, Shuangshuang;
    • Zhang, Dianbao;
    • Lu, Xiaohui;
    • Leng, Qing;
    • Zhang, Mingzhi;
    • Zhu, Linan
    Publication type:
    Article
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18

    P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP‐108, A NOVEL AND SELECTIVE BCL‐2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000969444.32459.0c
    By:
    • Xu, Wei;
    • Feng, Ru;
    • Wang, LI;
    • Zhu, Huayuan;
    • Zhou, Keshu;
    • Fu, Xiaorui;
    • Jing, Hongmei;
    • Song, Yuqin;
    • Qi, Junyuan;
    • Cui, Guohui;
    • LI, Fei;
    • Wang, Shaoyuan;
    • Zhou, Hui;
    • Qian, Wenbin;
    • Cai, Qingqing;
    • Zhao, Xielan;
    • Guo, Xutao;
    • Wei, Xiaolei;
    • Lin, Ningjing;
    • Xu, Zhongyuan
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37

    Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.

    Published in:
    Annals of Hematology, 2014, v. 93, n. 11, p. 1889, doi. 10.1007/s00277-014-2136-7
    By:
    • Zhou, Zhiyuan;
    • Li, Xiang;
    • Chen, Changying;
    • Li, Xin;
    • Zhang, Lei;
    • Li, Ling;
    • Wang, Xinhua;
    • Ma, Wang;
    • Fu, Xiaorui;
    • Wu, Jingjing;
    • Sun, Zhenchang;
    • Zhang, Xudong;
    • Li, Zhaoming;
    • Yan, Jiaqin;
    • Chang, Yu;
    • Lu, Lisha;
    • Qin, Beibei;
    • Li, Xiaoli;
    • Wen, Jianguo;
    • Zhang, Mingzhi
    Publication type:
    Article
    38
    39
    40
    41
    42

    Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial.

    Published in:
    Cancer Biology & Medicine, 2022, v. 19, n. 7, p. 1089, doi. 10.20892/j.issn.2095-3941.2021.0026
    By:
    • Jingjing Wu;
    • Fenghua Gao;
    • Wenhua Wang;
    • Xudong Zhang;
    • Meng Dong;
    • Lei Zhang;
    • Xin Li;
    • Ling Li;
    • Zhenchang Sun;
    • Xinhua Wang;
    • Xiaorui Fu;
    • Linan Zhu;
    • Mengjie Ding;
    • Songtao Niu;
    • Zhaoming Li;
    • Yu Chang;
    • Feifei Nan;
    • Jiaqian Yan;
    • Hui Yu;
    • Xiaolong Wu
    Publication type:
    Article
    43
    44
    45
    46
    47

    Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study.

    Published in:
    Cancer Management & Research, 2019, v. 11, p. 1363, doi. 10.2147/CMAR.S192143
    By:
    • Ma, Qianwen;
    • Chang, Yu;
    • Li, Ling;
    • Li, Xin;
    • Wang, Xinhua;
    • Wu, Jingjing;
    • Fu, Xiaorui;
    • Sun, Zhenchang;
    • Yu, Hui;
    • Zhang, Xudong;
    • Zhou, Zhiyuan;
    • Nan, Feifei;
    • Li, Zhaoming;
    • Liu, Xiyang;
    • Zhao, Qian;
    • Li, Yang;
    • Zhang, Lan;
    • Zhang, Mingzhi;
    • Zhang, Lei
    Publication type:
    Article
    48
    49
    50